Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients | Zendy

Kirsten L. White | Zendy; Rima Kulkarni | Zendy; Michael D. Miller | Zendy

Open Access

Analysis of early resistance development at the first failure timepoint in elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate-treated patients

Author(s) -

Kirsten L. White,

Rima Kulkarni,

Michael D. Miller

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv149

Subject(s) - elvitegravir , cobicistat , emtricitabine , resistance mutation , rilpivirine , medicine , population , tenofovir alafenamide , drug resistance , regimen , virology , viral load , biology , human immunodeficiency virus (hiv) , genetics , reverse transcriptase , antiretroviral therapy , rna , environmental health , gene

The patterns of emergent HIV-1 drug resistance in patients failing a single-tablet regimen consisting of elvitegravir, boosted by cobicistat, plus emtricitabine and tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) include mutations in HIV-1 reverse transcriptase (RT) and integrase (IN). The order of development of mutations at early virological failure has not been described. The aim of this study was to determine the first resistance mutations to emerge during virological failure on EVG/COBI/FTC/TDF.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research